PLUS THERAPEUTICS, Inc. Common Stock (PSTV) Stock Price

PSTVStock
$2.9675.62%52W
Market Cap$20.38M
P/E
PEG Ratio2.45
Div yield
Beta1.51

PSTV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-69.38%
Price vs S&P 500 (4W)-24.33%
PEG Ratio2.45
VGM Score43.66

PSTV Earnings Surprise History

Q2 25-0.16est. -3.25
Q3 25-1.00est. -0.88
Q4 250.00est. -0.92
Q1 26-1.05est. -0.87

PSTV Analyst Recommendations

Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.10
4.10

Industry Peers — Surgical & Medical Instruments(140)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PSTVPLUS THERAPEUTICS, Inc. Common Stock
CBF$2.96
SYKStryker CorporationCBC$330.59
MMM3M CompanyCDB$179.37
BSXBoston Scientific Corp.CBD$49.86
BDXBecton, Dickinson and Co.BDB$189.78
MDLNMedline Inc. Class A common stockCDC$35.64
RMDResMed Inc.CBC$236.59
DXCMDexCom, Inc.DBB$89.16
WSTWest Pharmaceutical Services, Inc.DCB$348.48
SOLVSolventum CorporationCCB$91.61
BAXBaxter International Inc.BDB$26.29

About PLUS THERAPEUTICS, Inc. Common Stock

Plus Therapeutics is a clinical-stage pharmaceutical company developing treatments for CNS cancers, including recurrent glioblastoma and leptomeningeal metastases. Its lead candidate, rhenium-186 obisbemeda, is a targeted radiotherapeutic designed for cancers with limited treatment options, including pediatric brain cancers.